Orasure Technologies (OSUR) 8.13 $OSUR
OraSure (OSUR) Is in Oversold Territory: What's Next? - Tale of the Tape
Zacks Equity Research - Zacks Investment Research - Tue Feb 10, 6:20AM CST
OraSure (OSUR) Is in Oversold Territory: What’s Next?
OSUR: 8.13 (+0.06)
Midday Gainers / Losers
Seeking Alpha - at Seeking Alpha - Thu Feb 05, 11:45AM CST
IMMU: 3.84 (unch), AXGN: 3.45 (+0.02), CLW: 63.20 (-0.74), QKLS: 2.10 (-0.24), EOPN: 8.55 (-0.01), HSNI: 67.32 (+1.52), LQDT: 9.52 (+0.09), EOX: 1.15 (unch), GLUU: 5.12 (+0.14), WSTL: 1.45 (+0.10), LFVN: 1.11 (-0.02), HSP: 87.35 (unch), GENE: 8.04 (+1.90), ADEP: 6.93 (-0.30), EARS: 5.88 (-0.01), IVC: 17.13 (+0.15), QUIK: 2.17 (+0.01), ENRJ: 2.81 (+0.06), FARM: 24.00 (-0.19), OSUR: 8.13 (+0.06)
Global Point of Care Diagnostic Testing Markets Analysis 2014: Detailed Analysis of 25 Individual Country Markets
M2 - Thu Feb 05, 2:43AM CST
Research and Markets (http://www.researchandmarkets.com/research/2mh8jd/point_of_care) has announced the addition of the "Global Point of Care Diagnostic Testing Markets Analysis 2014: Detailed Analysis of 25 Individual Country Markets" report to their offering. The report describes latest developments in the point of care testing market segment. It examines clinical instruments, devices and reagents and supplies as utilized in near-patient environments like hospital emergency rooms, critical care units, clinics and doctor's offices. The study defines the dollar volume of point of care sales and makes five year projections--both in the U.S. and worldwide--including Europe, Asia and Latin America. It also examines in detail the point of care sector for 25 individual country markets. A detailed summary of all important instruments in each clinical market is provided with emphasis on newly introduced products. Moreover, parallel areas where rapid detection is important using hand-held devices such as rapid detection of food pathogens and infectious diseases (MRSA, herpes simplex, avian flu, West Nile virus and typhoid) are discussed. Growth moderators and developing trends in point of care applications, as well as technology platform innovations and connectivity questions are examined in detail. The report surveys almost all of the companies known to be marketing, manufacturing or developing instruments and reagents for the point of care market in the U.S. and worldwide. Each company is discussed in depth, with a section on its history, product lines, business and marketing analysis, and a subjective commentary of the company's market position. Detailed tables and charts with sales forecasts and market data are also included. Key Topics Covered: 1. Overview 2. Overview of Diagnostic Testing Point of Care Markets 3. Summary Analysis of the Global POCT Market: Value, Growth Rates and Market Share 4. Analysis of the U.S. POCT Market: Value, Growth Rates and Market Share 5. Analysis of the European POCT Market: Value, Growth Rates and Market Shares 6. Analysis of the POCT Markets for Japan, China and India: Value, Growth Rates and Market Share 7. Analysis of the Rest of World (ROW) POCT Market: Value, Growth Rates and Market Share 8. Review of the Market Segments, Reagents and Equipment 9. POCT: Growth Regulators 10. Business Trends in the POC Sector 11. Technology Platform Innovations in POCT 12. Data Management and Connectivity 13. Corporate Profiles 14. POCT Sector Trends and Forecasts 15. New Entrants to the Point of Care Market Selection of 30 Companies: Click the link below to view the full extensive list featured in this report - Abaxis, Inc. - Abbott Laboratories - Acrongenomics - AgaMatrix - Augurix Diagnostics Ltd. - Axis-Shield Plc (Alere) - Axxin - Bayer Corp - Chembio Diagnostic, Inc. - Home Diagnostics (Nipro Diagnostics) - Medix Biochemica - MedMira Laboratories - MELA Sciences (Formerly Electro-Optical Sciences) - A. Menarini Diagnostics - Meretek Diagnostics Group - Nexus/ITC - Nova Biomedical - OraSure Technologies, Inc. - Orion Diagnostica - Polymedco, Inc. - Polymer Technology Systems, Inc. - Prima Biomedical Company - QBC Diagnostics - Qualigen - Selfcare, Inc. - Shanghai Ruicare Medical Co., Ltd. - Shenzhen Fitconn Technology Co., Ltd. - Siemens AG - Siloam Biosciences, Inc. - V?samed, Inc. For more information visit http://www.researchandmarkets.com/research/2m...nt_of_care
ABT: 46.09 (+0.87), MELA: 1.55 (+0.09), ABAX: 60.93 (+0.65), OSUR: 8.13 (+0.06)
OraSure Technologies (OSUR) CEO Douglas Michels on Q4 2014 Results - Earnings Call Transcript
SA Transcripts - at Seeking Alpha - Wed Feb 04, 9:53PM CST
OSUR: 8.13 (+0.06)
OraSure Technologies (OSUR) Q4 2014 Results - Earnings Call Webcast
SA Transcripts - at Seeking Alpha - Wed Feb 04, 3:55PM CST
OSUR: 8.13 (+0.06)
OraSure Technologies misses by $0.01, beats on revenue
Seeking Alpha - at Seeking Alpha - Wed Feb 04, 3:19PM CST
OSUR: 8.13 (+0.06)
OraSure Announces Full-Year and Fourth Quarter 2014 Financial Results
GlobeNewswire - Wed Feb 04, 3:06PM CST
OraSure Technologies, Inc. (Nasdaq:OSUR), a market leader in oral fluid diagnostics, today announced its consolidated financial results for the full-year and fourth quarter ended December 31, 2014.
OSUR: 8.13 (+0.06)
Notable earnings after Wednesday's close
Seeking Alpha - at Seeking Alpha - Tue Feb 03, 4:35PM CST
CNW: 45.26 (+1.09), HI: 30.28 (+0.01), PRU: 80.33 (+1.63), BGC: 14.40 (+0.51), ENS: 62.53 (+0.98), ADEP: 6.93 (-0.30), PRE: 119.71 (-0.07), APU: 51.14 (+0.18), FOXA: 34.72 (+0.31), BKD: 37.27 (+0.68), MUSA: 71.09 (-0.44), OSUR: 8.13 (+0.06), MTRX: 19.92 (+0.77), GIL: 59.48 (+0.23), CDNS: 18.02 (+0.10), NXPI: 84.79 (-0.60), LNC: 58.44 (+0.38), ALL: 71.46 (-0.11), LCI: 57.78 (-0.91), HUBG: 39.46 (+0.01), FORM: 8.50 (-0.02), ESS: 226.69 (-1.30), CMRE: 19.60 (+0.30), NE: 18.54 (+0.30), G: 21.48 (-0.09), CLW: 63.20 (-0.74), AFOP: 16.51 (+0.03), GMCR: 118.53 (+0.56), GLUU: 5.12 (+0.14), PAA: 51.48 (+0.16), AWH: 40.50 (-0.19), AFFX: 11.45 (+0.02), ATML: 8.39 (+0.09), PMT: 21.64 (+0.05), CINF: 52.46 (+0.27), P: 15.44 (+0.45), GPRE: 25.50 (-0.56), EPM: 6.70 (+0.07), BDN: 16.45 (-0.17), IRBT: 31.16 (+0.18), ININ: 42.99 (+0.14), CBG: 34.96 (-0.17), BMR: 22.85 (-0.13), GEOS: 19.15 (+0.02), PNNT: 9.40 (+0.16), FBHS: 46.58 (+1.02), MTGE: 18.33 (+0.01), ORLY: 205.55 (-1.02), FMC: 63.68 (+0.44), EXAR: 10.75 (-0.06), CATM: 37.02 (-0.37), ACXM: 19.10 (unch), FEIC: 79.99 (+0.87), PAGP: 27.84 (+0.04), CEB: 79.35 (+0.93), DATA: 99.90 (+1.40), MAC: 85.88 (-1.33), MAA: 73.82 (-0.59)
Commit To Purchase OraSure Technologies At $7.50, Earn 8.6% Annualized Using Options
at The Street - Thu Jan 29, 10:40AM CST
Investors eyeing a purchase of OraSure Technologies Inc. shares, but tentative about paying the going market price of $9.74/share, might benefit from considering selling puts among the alternative strategies at their disposal.
OSUR: 8.13 (+0.06)
Zimmer (ZMH) Q4 Earnings Beat, Revenues Miss Estimates - Analyst Blog
Zacks Equity Research - Zacks Investment Research - Thu Jan 29, 10:13AM CST
Zimmer Holdings (ZMH) reported fourth-quarter 2014 adjusted earnings per share (EPS) of $1.71, up 3% year over year.
MGNX: 34.09 (+0.10), ZMH: 119.33 (+1.18), CSII: 35.69 (+0.17), OSUR: 8.13 (+0.06)
Trade-Ideas: OraSure Technologies (OSUR) Is Today's Strong And Under The Radar Stock
at The Street - Mon Jan 26, 9:42AM CST
Trade-Ideas LLC identified OraSure Technologies (OSUR) as a strong and under the radar candidate
OSUR: 8.13 (+0.06)
21.1% Return Seen to Date on SmarTrend OraSure Technologies Call (OSUR)
Comtex SmarTrend(R) - Mon Jan 26, 9:27AM CST
SmarTrend identified an Uptrend for OraSure Technologies (NASDAQ:OSUR) on October 13th, 2014 at $8.09. In approximately 4 months, OraSure Technologies has returned 21.09% as of today's recent price of $9.79.
OSUR: 8.13 (+0.06)
OraSure Technologies Has Returned 25.3% Since SmarTrend Recommendation (OSUR)
Comtex SmarTrend(R) - Fri Jan 16, 5:19PM CST
SmarTrend identified an Uptrend for OraSure Technologies (NASDAQ:OSUR) on October 13th, 2014 at $8.09. In approximately 3 months, OraSure Technologies has returned 25.29% as of today's recent price of $10.13.
OSUR: 8.13 (+0.06)
St. Jude Medical (STJ) Announces Preliminary Q4 Results - Analyst Blog
Zacks Equity Research - Zacks Investment Research - Thu Jan 15, 11:00AM CST
St. Jude Medical, Inc.'s (STJ) fourth-quarter revenues are estimated to grow 1% year over year to around $1.44 billion, which is in line with the current Zacks Consensus Estimate.
ICUI: 88.98 (+0.42), CNAT: 5.92 (+0.10), STJ: 67.48 (+0.65), OSUR: 8.13 (+0.06)
Orasure reports February 4
Seeking Alpha - at Seeking Alpha - Wed Jan 14, 6:19AM CST
OSUR: 8.13 (+0.06)
OraSure Technologies Earnings Conference Call Invitation
GlobeNewswire - Wed Jan 14, 5:27AM CST
OraSure Technologies, Inc. (Nasdaq:OSUR) has scheduled its regular earnings conference call covering 2014 full year and fourth quarter results and certain 2015 financial guidance for 5:00 pm ET (2:00 pm PT) on Wednesday, February 4, 2015. An update on certain business developments will also be provided.
OSUR: 8.13 (+0.06)
A Company's First Profit Can Mean Big Profits to Investors - Screen of the Week
Kevin Matras - Zacks Investment Research - Tue Jan 13, 12:00AM CST
A Company's First Profit Can Mean Big Profits to Investors - Screen of the Week
INCY: 75.94 (+0.28), OPHT: 51.11 (+0.12), AGIO: 118.55 (+0.11), OSUR: 8.13 (+0.06), XNPT: 6.69 (-0.21)
HSR Approval Time Extended in Wright Medical-Tornier Deal - Analyst Blog
Zacks Equity Research - Zacks Investment Research - Fri Jan 02, 3:50PM CST
Specialty orthopedic company, Wright Medical Group Inc. (WMGI), recently announced that Tornier N.V. (TRNX) has voluntarily withdrawn and refiled its Hart-Scott-Rodino ("HSR"
notification and report form.
ICUI: 88.98 (+0.42), WMGI: 25.68 (+0.17), TRNX: 25.32 (+0.12), OSUR: 8.13 (+0.06)
OraSure (OSUR) Is in Oversold Territory: What's Next? - Tale of the Tape
Zacks Equity Research - Zacks Investment Research - Tue Feb 10, 6:20AM CST
OraSure (OSUR) Is in Oversold Territory: What’s Next?
OSUR: 8.13 (+0.06)
Midday Gainers / Losers
Seeking Alpha - at Seeking Alpha - Thu Feb 05, 11:45AM CST
IMMU: 3.84 (unch), AXGN: 3.45 (+0.02), CLW: 63.20 (-0.74), QKLS: 2.10 (-0.24), EOPN: 8.55 (-0.01), HSNI: 67.32 (+1.52), LQDT: 9.52 (+0.09), EOX: 1.15 (unch), GLUU: 5.12 (+0.14), WSTL: 1.45 (+0.10), LFVN: 1.11 (-0.02), HSP: 87.35 (unch), GENE: 8.04 (+1.90), ADEP: 6.93 (-0.30), EARS: 5.88 (-0.01), IVC: 17.13 (+0.15), QUIK: 2.17 (+0.01), ENRJ: 2.81 (+0.06), FARM: 24.00 (-0.19), OSUR: 8.13 (+0.06)
Global Point of Care Diagnostic Testing Markets Analysis 2014: Detailed Analysis of 25 Individual Country Markets
M2 - Thu Feb 05, 2:43AM CST
Research and Markets (http://www.researchandmarkets.com/research/2mh8jd/point_of_care) has announced the addition of the "Global Point of Care Diagnostic Testing Markets Analysis 2014: Detailed Analysis of 25 Individual Country Markets" report to their offering. The report describes latest developments in the point of care testing market segment. It examines clinical instruments, devices and reagents and supplies as utilized in near-patient environments like hospital emergency rooms, critical care units, clinics and doctor's offices. The study defines the dollar volume of point of care sales and makes five year projections--both in the U.S. and worldwide--including Europe, Asia and Latin America. It also examines in detail the point of care sector for 25 individual country markets. A detailed summary of all important instruments in each clinical market is provided with emphasis on newly introduced products. Moreover, parallel areas where rapid detection is important using hand-held devices such as rapid detection of food pathogens and infectious diseases (MRSA, herpes simplex, avian flu, West Nile virus and typhoid) are discussed. Growth moderators and developing trends in point of care applications, as well as technology platform innovations and connectivity questions are examined in detail. The report surveys almost all of the companies known to be marketing, manufacturing or developing instruments and reagents for the point of care market in the U.S. and worldwide. Each company is discussed in depth, with a section on its history, product lines, business and marketing analysis, and a subjective commentary of the company's market position. Detailed tables and charts with sales forecasts and market data are also included. Key Topics Covered: 1. Overview 2. Overview of Diagnostic Testing Point of Care Markets 3. Summary Analysis of the Global POCT Market: Value, Growth Rates and Market Share 4. Analysis of the U.S. POCT Market: Value, Growth Rates and Market Share 5. Analysis of the European POCT Market: Value, Growth Rates and Market Shares 6. Analysis of the POCT Markets for Japan, China and India: Value, Growth Rates and Market Share 7. Analysis of the Rest of World (ROW) POCT Market: Value, Growth Rates and Market Share 8. Review of the Market Segments, Reagents and Equipment 9. POCT: Growth Regulators 10. Business Trends in the POC Sector 11. Technology Platform Innovations in POCT 12. Data Management and Connectivity 13. Corporate Profiles 14. POCT Sector Trends and Forecasts 15. New Entrants to the Point of Care Market Selection of 30 Companies: Click the link below to view the full extensive list featured in this report - Abaxis, Inc. - Abbott Laboratories - Acrongenomics - AgaMatrix - Augurix Diagnostics Ltd. - Axis-Shield Plc (Alere) - Axxin - Bayer Corp - Chembio Diagnostic, Inc. - Home Diagnostics (Nipro Diagnostics) - Medix Biochemica - MedMira Laboratories - MELA Sciences (Formerly Electro-Optical Sciences) - A. Menarini Diagnostics - Meretek Diagnostics Group - Nexus/ITC - Nova Biomedical - OraSure Technologies, Inc. - Orion Diagnostica - Polymedco, Inc. - Polymer Technology Systems, Inc. - Prima Biomedical Company - QBC Diagnostics - Qualigen - Selfcare, Inc. - Shanghai Ruicare Medical Co., Ltd. - Shenzhen Fitconn Technology Co., Ltd. - Siemens AG - Siloam Biosciences, Inc. - V?samed, Inc. For more information visit http://www.researchandmarkets.com/research/2m...nt_of_care
ABT: 46.09 (+0.87), MELA: 1.55 (+0.09), ABAX: 60.93 (+0.65), OSUR: 8.13 (+0.06)
OraSure Technologies (OSUR) CEO Douglas Michels on Q4 2014 Results - Earnings Call Transcript
SA Transcripts - at Seeking Alpha - Wed Feb 04, 9:53PM CST
OSUR: 8.13 (+0.06)
OraSure Technologies (OSUR) Q4 2014 Results - Earnings Call Webcast
SA Transcripts - at Seeking Alpha - Wed Feb 04, 3:55PM CST
OSUR: 8.13 (+0.06)
OraSure Technologies misses by $0.01, beats on revenue
Seeking Alpha - at Seeking Alpha - Wed Feb 04, 3:19PM CST
OSUR: 8.13 (+0.06)
OraSure Announces Full-Year and Fourth Quarter 2014 Financial Results
GlobeNewswire - Wed Feb 04, 3:06PM CST
OraSure Technologies, Inc. (Nasdaq:OSUR), a market leader in oral fluid diagnostics, today announced its consolidated financial results for the full-year and fourth quarter ended December 31, 2014.
OSUR: 8.13 (+0.06)
Notable earnings after Wednesday's close
Seeking Alpha - at Seeking Alpha - Tue Feb 03, 4:35PM CST
CNW: 45.26 (+1.09), HI: 30.28 (+0.01), PRU: 80.33 (+1.63), BGC: 14.40 (+0.51), ENS: 62.53 (+0.98), ADEP: 6.93 (-0.30), PRE: 119.71 (-0.07), APU: 51.14 (+0.18), FOXA: 34.72 (+0.31), BKD: 37.27 (+0.68), MUSA: 71.09 (-0.44), OSUR: 8.13 (+0.06), MTRX: 19.92 (+0.77), GIL: 59.48 (+0.23), CDNS: 18.02 (+0.10), NXPI: 84.79 (-0.60), LNC: 58.44 (+0.38), ALL: 71.46 (-0.11), LCI: 57.78 (-0.91), HUBG: 39.46 (+0.01), FORM: 8.50 (-0.02), ESS: 226.69 (-1.30), CMRE: 19.60 (+0.30), NE: 18.54 (+0.30), G: 21.48 (-0.09), CLW: 63.20 (-0.74), AFOP: 16.51 (+0.03), GMCR: 118.53 (+0.56), GLUU: 5.12 (+0.14), PAA: 51.48 (+0.16), AWH: 40.50 (-0.19), AFFX: 11.45 (+0.02), ATML: 8.39 (+0.09), PMT: 21.64 (+0.05), CINF: 52.46 (+0.27), P: 15.44 (+0.45), GPRE: 25.50 (-0.56), EPM: 6.70 (+0.07), BDN: 16.45 (-0.17), IRBT: 31.16 (+0.18), ININ: 42.99 (+0.14), CBG: 34.96 (-0.17), BMR: 22.85 (-0.13), GEOS: 19.15 (+0.02), PNNT: 9.40 (+0.16), FBHS: 46.58 (+1.02), MTGE: 18.33 (+0.01), ORLY: 205.55 (-1.02), FMC: 63.68 (+0.44), EXAR: 10.75 (-0.06), CATM: 37.02 (-0.37), ACXM: 19.10 (unch), FEIC: 79.99 (+0.87), PAGP: 27.84 (+0.04), CEB: 79.35 (+0.93), DATA: 99.90 (+1.40), MAC: 85.88 (-1.33), MAA: 73.82 (-0.59)
Commit To Purchase OraSure Technologies At $7.50, Earn 8.6% Annualized Using Options
at The Street - Thu Jan 29, 10:40AM CST
Investors eyeing a purchase of OraSure Technologies Inc. shares, but tentative about paying the going market price of $9.74/share, might benefit from considering selling puts among the alternative strategies at their disposal.
OSUR: 8.13 (+0.06)
Zimmer (ZMH) Q4 Earnings Beat, Revenues Miss Estimates - Analyst Blog
Zacks Equity Research - Zacks Investment Research - Thu Jan 29, 10:13AM CST
Zimmer Holdings (ZMH) reported fourth-quarter 2014 adjusted earnings per share (EPS) of $1.71, up 3% year over year.
MGNX: 34.09 (+0.10), ZMH: 119.33 (+1.18), CSII: 35.69 (+0.17), OSUR: 8.13 (+0.06)
Trade-Ideas: OraSure Technologies (OSUR) Is Today's Strong And Under The Radar Stock
at The Street - Mon Jan 26, 9:42AM CST
Trade-Ideas LLC identified OraSure Technologies (OSUR) as a strong and under the radar candidate
OSUR: 8.13 (+0.06)
21.1% Return Seen to Date on SmarTrend OraSure Technologies Call (OSUR)
Comtex SmarTrend(R) - Mon Jan 26, 9:27AM CST
SmarTrend identified an Uptrend for OraSure Technologies (NASDAQ:OSUR) on October 13th, 2014 at $8.09. In approximately 4 months, OraSure Technologies has returned 21.09% as of today's recent price of $9.79.
OSUR: 8.13 (+0.06)
OraSure Technologies Has Returned 25.3% Since SmarTrend Recommendation (OSUR)
Comtex SmarTrend(R) - Fri Jan 16, 5:19PM CST
SmarTrend identified an Uptrend for OraSure Technologies (NASDAQ:OSUR) on October 13th, 2014 at $8.09. In approximately 3 months, OraSure Technologies has returned 25.29% as of today's recent price of $10.13.
OSUR: 8.13 (+0.06)
St. Jude Medical (STJ) Announces Preliminary Q4 Results - Analyst Blog
Zacks Equity Research - Zacks Investment Research - Thu Jan 15, 11:00AM CST
St. Jude Medical, Inc.'s (STJ) fourth-quarter revenues are estimated to grow 1% year over year to around $1.44 billion, which is in line with the current Zacks Consensus Estimate.
ICUI: 88.98 (+0.42), CNAT: 5.92 (+0.10), STJ: 67.48 (+0.65), OSUR: 8.13 (+0.06)
Orasure reports February 4
Seeking Alpha - at Seeking Alpha - Wed Jan 14, 6:19AM CST
OSUR: 8.13 (+0.06)
OraSure Technologies Earnings Conference Call Invitation
GlobeNewswire - Wed Jan 14, 5:27AM CST
OraSure Technologies, Inc. (Nasdaq:OSUR) has scheduled its regular earnings conference call covering 2014 full year and fourth quarter results and certain 2015 financial guidance for 5:00 pm ET (2:00 pm PT) on Wednesday, February 4, 2015. An update on certain business developments will also be provided.
OSUR: 8.13 (+0.06)
A Company's First Profit Can Mean Big Profits to Investors - Screen of the Week
Kevin Matras - Zacks Investment Research - Tue Jan 13, 12:00AM CST
A Company's First Profit Can Mean Big Profits to Investors - Screen of the Week
INCY: 75.94 (+0.28), OPHT: 51.11 (+0.12), AGIO: 118.55 (+0.11), OSUR: 8.13 (+0.06), XNPT: 6.69 (-0.21)
HSR Approval Time Extended in Wright Medical-Tornier Deal - Analyst Blog
Zacks Equity Research - Zacks Investment Research - Fri Jan 02, 3:50PM CST
Specialty orthopedic company, Wright Medical Group Inc. (WMGI), recently announced that Tornier N.V. (TRNX) has voluntarily withdrawn and refiled its Hart-Scott-Rodino ("HSR"
notification and report form. ICUI: 88.98 (+0.42), WMGI: 25.68 (+0.17), TRNX: 25.32 (+0.12), OSUR: 8.13 (+0.06)
